Pacific Biosciences of California (PACB)
(Real Time Quote from BATS)
$1.92 USD
+0.12 (6.67%)
Updated Jul 23, 2024 10:46 AM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PACB 1.92 +0.12(6.67%)
Will PACB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PACB
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PacBio (PACB) and Form Bio to Boost AAV Industry Development
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
Other News for PACB
Novogene to Power Cancer, Rare Disease, and Environmental Research with PacBio Sequencing
PacBio announces Novogene is using its Revio
Dow Rallies To All-Time Highs, Small Caps Outperform Tech, Gold Hits Records On Heightened September Rate Cut Bets: What's Driving Markets Tuesday?
PacBio to Report Second Quarter 2024 Financial Results on August 7, 2024
Barclays Sticks to Their Hold Rating for Pacific Biosciences (PACB)